Active Biotech AB (publ) (STO:ACTI)

Active Biotech AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-37.32	-39.4	-45.8	-58.37	-49.83
Depreciation & Amortization	1.6	1.64	1.68	1.5	1.28
Stock-Based Compensation	-	0.01	0.17	0.69	0.28
Other Operating Activities	-	-	-	-	-0
Change in Accounts Receivable	1.11	-1.09	-0.17	0.03	0.99
Change in Other Net Operating Assets	2.22	-1.58	-1.62	1.31	1.1
Operating Cash Flow	-32.4	-40.42	-45.74	-54.85	-46.17
Sale (Purchase) of Intangibles	-	-	-	-0.25	-
Investing Cash Flow	-	-	-	-0.25	-
Long-Term Debt Repaid	-1.71	-1.64	-1.62	-1.76	-1.02
Net Debt Issued (Repaid)	-1.71	-1.64	-1.62	-1.76	-1.02
Issuance of Common Stock	78.53	35.19	43.47	46.83	76.25
Other Financing Activities	-6.72	-1.96	-1.68	-1.31	-2.15
Financing Cash Flow	70.1	31.59	40.16	43.76	73.09
Net Cash Flow	37.7	-8.82	-5.58	-11.34	26.92
Cash Interest Paid	-	0	0	-	0
Levered Free Cash Flow	-7.03	-34.26	-29.14	-32.65	-27.12
Unlevered Free Cash Flow	-6.96	-34.15	-28.99	-32.53	-27.1
Change in Working Capital	3.33	-2.67	-1.79	1.34	2.1

Source: S&P Global Market Intelligence. Standard template. Financial Sources.